Turning Point Therapeutics, Inc. TPTX
At closeAug 15, 2022, 4:00 PM EDT
52-week range unavailable
- Market cap
- 3.81B
- Revenue (ttm)
- 1.01M
- Shares out
- 50.07M
- Forward P/E
- -10.54
- Volume
- 1.03M
- Open
- 75.32
- Previous close
- 75.49
- Day's range
- 75.30 – 75.77
- Beta
- -0.19
- Analysts
- Hold
- Price target
- 71.50 (-5.3%)
- Earnings date
- Aug 8, 2022
Key statistics
- Enterprise value
- 2.99B
- PEG ratio
- 0.00
- Price / sales
- 3775.94
- Price / book
- 4.78
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -97.70%
- Free cash flow
- -136.76M
- Total cash
- 818.29M
- Total debt
- 4.94M
- Return on equity
- -36.80%
- Short % of float
- 4.51%
- 50-day average
- 75.21
- 200-day average
- 46.90
Analyst view
Consensus: hold
- Target (low)
- 58.00
- Target (mean)
- 71.50
- Target (high)
- 76.00
- Strong buy1
- Buy0
- Hold8
- Sell0
- Strong sell0
Next earnings
Aug 8, 2022
Expected Aug 8, 2022. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 8, 2022 | Jun 1, 2022 | -1.78 | — | — | — |
| May 10, 2022 | Mar 1, 2022 | -1.45 | — | — | — |
| Feb 28, 2022 | Dec 1, 2021 | -1.40 | — | — | — |
| Nov 9, 2021 | Sep 1, 2021 | -1.26 | — | — | — |
| Aug 9, 2021 | Jun 1, 2021 | -1.20 | — | — | — |
| May 5, 2021 | Mar 1, 2021 | -0.58 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 13, 2022 | SVB Leerink | down | Outperform | Market Perform |
| Jun 6, 2022 | Cowen & Co. | down | Outperform | Market Perform |
| Jun 6, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 3, 2022 | Wedbush | down | Outperform | Neutral |
| May 24, 2022 | Goldman Sachs | main | — | Buy |
| May 20, 2022 | B of A Securities | init | — | Buy |
About Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tptherapeutics.com
News
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics 
TPTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Turning Point Therapeutics, Inc. Is Fair to Shareholders 
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX 
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX 
Biotech ETFs Strengthen as Bristol Myers Squibb Buys Turning Point 
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Turning Point Therapeutics, Inc. Buyout 
Turning Point Therapeutics' Shares Soar on Bristol-Myers Squibb Deal 
SHAREHOLDER ALERT: Weiss Law Investigates Turning Point Therapeutics, Inc. 
Here is Why Turning Point Therapeutics Jumped 110% 
Turning Point Therapeutics shares more than doubled on Friday
Your note
Sign in to keep a note on TPTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLES MARK J | Director | Purchase | Jun 20, 2021 | 2,000 |
| BAKER BRIAN LEE | Officer | Sale | Mar 22, 2021 | 4,116 |
| COUNTOURIOTIS ATHENA M | Chief Executive Officer | Stock Award(Grant) | Feb 8, 2022 | 110,330 |
| HIRMAND MOHAMMAD | Officer | Stock Award(Grant) | Feb 8, 2022 | 40,821 |
| NORTH ANNETTE | General Counsel | Stock Award(Grant) | Feb 8, 2022 | 27,979 |
| PARTRIDGE ANDREW JOHN | Officer | Stock Award(Grant) | Feb 8, 2022 | 38,361 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 8.30% | 4,157,552 | 316.02M | Jun 29, 2022 |
| Blackrock Inc. | 7.57% | 3,791,801 | 288.21M | Jun 29, 2022 |
| Cormorant Asset Management, LP | 4.96% | 2,484,220 | 188.83M | Jun 29, 2022 |
| Federated Hermes, Inc. | 4.14% | 2,075,037 | 157.72M | Mar 30, 2022 |
| AllianceBernstein, L.P. | 4.06% | 2,035,049 | 154.68M | Mar 30, 2022 |
| Orbimed Advisors LLC. | 4.02% | 2,012,250 | 152.95M | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Specialized-Health Care Fund | 2.59% | 1,296,184 | 98.52M | Apr 29, 2022 |
| Price (T.Rowe) New Horizons Fund | 2.51% | 1,259,029 | 95.70M | Mar 30, 2022 |
| Vanguard Total Stock Market Index Fund | 2.32% | 1,150,487 | 87.45M | Mar 30, 2022 |
| iShares Russell 2000 ETF | 2.08% | 1,033,004 | 78.52M | Jun 29, 2022 |
| Federated Hermes Kaufmann Small Cap Fund | 2.03% | 1,015,600 | 77.20M | Apr 29, 2022 |
| Federated Hermes Kaufmann Fund | 2.00% | 1,000,000 | 76.01M | Apr 29, 2022 |